<DOC>
	<DOC>NCT01163253</DOC>
	<brief_summary>The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.</brief_summary>
	<brief_title>A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description>The study terminated on 08MAR2016 as it met its objectives of characterizing long term safety and tolerability. The study did not terminate due to safety concerns.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Have participated in qualifying study with CP690,550 and are 18 years or older with diagnosis of plaquetype psoriasis (psoriasis vulgaris). Nonplaque or drug induced forms of psoriasis; Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB). Any uncontrolled significant medical condition.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>chronic</keyword>
	<keyword>severe</keyword>
	<keyword>treatment</keyword>
	<keyword>safety</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>Tofacitinib</keyword>
</DOC>